Ann: Launch of 90 gram pack size of Dapsone 5%, Gel in US, page-3

Years back ACR said they are aiming for double digit returns on each generic. So if a generic is costing some $3.000,000 to $3,500,000 from development to market, and if double digit returns are (hopefully ) around 15%, we are potentially looking only at $450,000 to $525,000 returns (that have to be shared with our partners?) . So it will only be volume ANDA approvals and launches that will make any serious money. The up side is winning generics can last decades. The downside is, does ACR have the know how to pick winning ANDA formulas? I not sure that they do. Jet